A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001
Geoffrey L. Uy(Memorial Sloan Kettering Cancer Center), Richard A. Larson(Urbana University), Wendy Stock(University of Chicago), Heidi D. Klepin(Wake Forest University), Maria R. Baer(University of Maryland, Baltimore), Ben L. Sanford(Duke University), Kristina Laumann(Goethe University Frankfurt), Guido Marcucci(City of Hope), Clara D. Bloomfield(North Shore University Hospital), Richard M. Stone(Dana-Farber Cancer Institute), Weiqiang Zhao(Harbin Institute of Technology), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Mark J. Levis(Sidney Kimmel Cancer Center), Peter Westervelt(MACOM (United States)), Sumithra J. Mandrekar(Mayo Clinic), Bayard L. Powell(Atrium Health Wake Forest Baptist), William Blum(The Ohio State University)
Cited by 66
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k